TFF Pharmaceuticals, Inc. Common Stock
TFFP
TFFP was delisted on the 12th of December, 2024.
40 hedge funds and large institutions have $4.04M invested in TFF Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
34% more capital invested
Capital invested by funds: $3.02M → $4.04M (+$1.03M)
21% more funds holding
Funds holding: 33 → 40 (+7)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.35M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$412K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$96.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.7K |
| 5 |
Renaissance Technologies
New York
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$13.8K |
| 2 |
Millennium Management
New York
|
-$5.14K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.55K |
| 4 |
PCM
Princeton Capital Management
Red Bank,
New Jersey
|
-$871 |
| 5 |
WIM
Westside Investment Management
Santa Monica,
California
|
-$384 |
TFFP Hedge Fund Activity: Q3 2023 in Review
40 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TFF Pharmaceuticals, Inc. Common Stock (TFFP) for Q3 2023, worth a combined $4.04M — up 34% from $3.02M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TFFP positions and 1 closed out — a net gain of 7 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Carlson Capital, adding an estimated $1.35M. The largest seller was UBS Group, cutting an estimated $13.8K.
- 40 institutional investors held TFF Pharmaceuticals, Inc. Common Stock (TFFP) as of Q3 2023, up from 33 in Q2 2023.
- Funds reported $4.04M of TFF Pharmaceuticals, Inc. Common Stock stock for Q3 2023, up 34% quarter-over-quarter.
- 8 funds opened new TFF Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +7 holders.
- The largest TFF Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Carlson Capital, an estimated $1.35M added.
- The largest TFF Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was UBS Group, an estimated $13.8K sold.
Based on aggregated 13F filings for Q3 2023.